Pneumonia is an important cause of morbidity and mortality in intensive care. Three types of pneumonia are relevant to intensive care. These are communityacquired, hospital-acquired and ventilator-associated pneumonia. The latter two types of pneumonia are nosocomial in nature and at least in part represent a failure of cross-infection precautions and health delivery systems. Ventilator-associated pneumonia is particularly important because it trebles the length of stay in intensive care and adds substantially to costs 1 . The outcome for all types of pneumonia is determined partly by host factors, but also by early diagnosis and effective antibiotic therapy.
Over-diagnosis of pneumonia inevitably leads to increased use of antibiotics. The intensive care unit is often considered the epicentre of bacterial resistance in a hospital and over-use of antibiotics is an associated factor. Other factors include nursing ratios, overcrowding, lack of hand hygiene and other hygienic practices, cross-transmission of resistant strains and the vulnerability of patients in intensive care. Late or missed diagnosis delays appropriate therapy, and increases mortality, intensive care and hospital length of stay and cost.
The diagnosis of community-acquired pneumonia is frequently straightforward, as fever, clinical signs and radiological changes pave the way. Only a small percentage of patients presenting to hospital are admitted to intensive care and criteria for admission vary amongst physicians, hospitals and regions. Criteria for severe community-acquired pneumonia have been developed and subsequently accepted by the American Thoracic Society 2 . These criteria are highly specific and will allow stratification for study purposes 3 . By comparison, the diagnosis of pneumonia in the ventilated patient is often difficult. In the ventilated patient, lung infection frequently occurs on a background of chronic lung disease, acute respiratory distress syndrome and bacterial colonization of the airway. In addition, ventilation itself is a source of lung injury and further complicates the picture. In this context, radiological features on standard imaging and culture of tracheal aspirates are sensitive but of low specificity.
This issue features three articles on the topic 4-6 . A prospective survey of 476 mechanically ventilated patients with pneumonia was carried out by members of the ANZICS Clinical Trials Group in 14 intensive care units. There were three components to the surveys: the spectrum of clinical practice, disease and mortality risk factors and prediction of physician confidence to diagnose pneumonia and predict outcome.
Several important findings emerged from these surveys. The mortality of pneumonia in patients requiring mechanical ventilation is high (24-37%), but similar for all three types of pneumonia and consistent with other reports. The use of bronchoscopy as an aid to diagnosis varies between hospitals (26% overall) and was not associated with outcome. Quantitative cultures were not available to many centres, and pleural fluid cultures, blood cultures and serology were infrequently performed. The diagnostic confidence of physicians was lower for nosocomial (hospital-acquired and ventilator-associated) pneumonia unless the condition was life-threatening. Despite these findings, appropriate antibiotics were prescribed for 87% of patients within the first 24 hours, one of the surprise features of the survey.
The findings from these surveys raise several issues. Firstly, the variability of clinical practice and level of diagnostic confidence is significant. On superficial examination this diversity does not appear to be associated with outcome but it is an obstacle to clinical trials and to the use of pneumonia in intensive care as a clinical indicator. The effectiveness of interventions to reduce the incidence of pneumonia and improve outcome can only be undertaken if robust criteria for diagnosis are accepted and if severe cases can be identified. The American Thoracic Society criteria are highly specific for severe communityacquired pneumonia and could be applied to other forms of pneumonia in intensive care, at least for stratification purposes 3 . In addition to the need for mechanical ventilation these include features of "septic shock" and other organ dysfunction. It may also be important to specify other laboratory markers of inflammation (e.g. CRP and/or procalcitonin), radiological criteria (either on standard imaging or CT scanning), retrieval of valid lower respiratory tract secretions by bronchoscopic protected brush specimens or alveolar lavage and quantitative analysis.
The Clinical Trials Group have created the oppor-tunity to define minimum criteria for the diagnosis of pneumonia in intensive care that can be used in units participating in prospective studies. The surveys also highlight that pneumonia remains an important cause of mortality in intensive care. For many patients, ventilator-associated pneumonia is part of a final common pathway to death, a co-morbidity combining with the primary pathology, acute respiratory distress syndrome and multiple organ dysfunction. Ventilatorassociated pneumonia can also be regarded as a clinical indicator as it often represents a failure of "quality" in intensive care. Whether this can be improved is questionable but undoubtedly worthy of major study. Many questions remain unanswered. Do specific diagnostic techniques for lower respiratory tract infection influence patterns of antibiotic usage and the development of resistance? What is the role of percutaneous lung needle aspiration, histopathological examination of lung tissue and simultaneous recovery of the same microorganism from cultures of respiratory secretions and blood in diagnosis? How important is it to have customized empiric antimicrobial choices based on local epidemiology surveillance programs? When specific diagnostic techniques do not confirm pneumonia, what further re-evaluation of fever and pulmonary infiltrates is indicated?
What standards for decontamination of ventilatory equipment and nursing care of ventilated patients should apply? Can the earlier use of non-invasive ventilation improve outcome? Should we be using heated humidifiers or heat and moisture exchangers, subglottic secretion drainage and kinetic beds? These questions can only be evaluated following the acceptance of standardized diagnostic criteria for pneumonia in clinical care.
The cooperative ventures of the ANZICS Clinical Trials Group are fast becoming a landmark feature of intensive care. Australia and New Zealand are fortunate to have relatively homogeneous, high-quality intensive care, a product of a relatively small and affluent population, certain geographic factors, highquality medical and nursing intensive care training programs and well established units. The Clinical Trials Group is well positioned to develop and answer important questions that can shape intensive care practice worldwide.
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